The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate‐to‐severe) allergic asthma
Abstract
Background: Patients with poorly controlled asthma have greater morbidity and mortality. This study evaluated the efficacy and tolerability of omalizumab in patients with poorly controlled, moderate‐to‐severe allergic asthma. Methods: This was a randomized, open‐label, multicentre, parallel‐group study. A total of 312 patients (12–73 years) receiving ≥400 μ g/day (adolescent) or ≥800 μ g/day (adult) inhaled beclomethasone dipropionate, or equivalent were included. Patients received best standard care (BSC) with or without omalizumab [at least 0.016 mg/kg/IgE (IU/ml) every 4 weeks] for 12 months. Results: The annualized mean number of asthma deterioration‐related incidents was reduced from 9.76 with BSC alone (n = 106) to 4.92 per patient‐year with omalizumab (n = 206) (P < 0.001). Mean clinically significant asthma exacerbation rates were 2.86 and 1.12 per patient‐year, respectively (P < 0.001). Omalizumab‐treated patients (41.4%) required rescue medication <1 day/week compared with 20.7% for BSC alone (P < 0.001). Omalizumab improved absolute forced expiratory volume in 1 s (FEV 1) compared with BSC alone (2.48 and 2.28l, respectively; P < 0.05) and reduced symptom scores relative to BSC alone (decrease of 6.5 and 0.7 respectively; P < 0.001). Omalizumab was well‐tolerated. Conclusions: Omalizumab administered as add‐on therapy to BSC benefits patients with poorly controlled, moderate‐to‐severe allergic asthma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Busse, W., Corren, J., Lanier, B. Q., McAlary, M., Fowler-Taylor, A., Cioppa, G. D., van As, A., & Gupta, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.117880 · Cited by 1,307
Solèr, M., Matz, J., Townley, R., Buhl, R., O'Brien, J., Fox, H., Thirlwell, J., Gupta, N., & Della Cioppa, G. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00092101 · Cited by 827
Self-citationThe role of allergy in the development of asthma
Holt, P. G., Macaubas, C., Stumbles, P. A., & Sly, P. D. (1999) · Nature · doi:10.1038/35037009 · Cited by 471
Barnes, P., Jonsson, B., & Klim, J. (1996) · European Respiratory Journal · doi:10.1183/09031936.96.09040636 · Cited by 434
Randomised comparison of guided self management and traditional treatment of asthma over one year
Lahdensuo, A., Haahtela, T., Herrala, J., Kava, T., Kiviranta, K., Kuusisto, P., Peramaki, E., Poussa, T., Saarelainen, S., & Svahn, T. (1996) · BMJ · doi:10.1136/bmj.312.7033.748 · Cited by 362
Holgate, S. T., Bousquet, J., Wenzel, S. E., Fox, H., Liu, J., & Castellsagué, J. (2001) · Current Medical Research and Opinion · doi:10.1185/0300799019117010 · Cited by 125
Self-citationWasserfallen, J.-B., Gold, K. F., Schulman, K. A., & Baraniuk, J. N. (1997) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(97)70189-1 · Cited by 97
IgE Inhibition as a Therapy for Allergic Disease
Jardieu, P. M., & Fick, R. B. (1999) · International Archives of Allergy and Immunology · doi:10.1159/000024043 · Cited by 58
Cited by
Humbert, M., Beasley, R., Ayres, J., Slavin, R., Hébert, J., Bousquet, J., Beeh, K. ‐., Ramos, S., Canonica, G. W., Hedgecock, S., et al. (2005) · Allergy · doi:10.1111/j.1398-9995.2004.00772.x · Cited by 1,123
Self-citationOmalizumab for asthma in adults and children
Normansell, R., Walker, S., Milan, S. J., Walters, E. H., & Nair, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003559.pub4 · Cited by 651
The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation
Holgate, S., Casale, T., Wenzel, S., Bousquet, J., Deniz, Y., & Reisner, C. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.11.053 · Cited by 466
Bousquet, J., Cabrera, P., Berkman, N., Buhl, R., Holgate, S., Wenzel, S., Fox, H., Hedgecock, S., Blogg, M., & Cioppa, G. D. (2005) · Allergy · doi:10.1111/j.1398-9995.2004.00770.x · Cited by 401
Self-citationFarne, H. A., Wilson, A., Powell, C., Bax, L., & Milan, S. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010834.pub3 · Cited by 315
Metadata
- Authors
- Ayres, J. G., Higgins, B., Chilvers, E. R., Ayre, G., Blogg, M., & Fox, H.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2004-06-04
- Volume
- 59
- Issue
- 7
- Pages
- 701-708
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W1987444459
- Cited by
- 279
- References
- 8
- FWCI
- 13.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate‐to‐severe) allergic asthma. https://app.cochat.ai/papers/10.1111/j.1398-9995.2004.00533.x
- The paper
- Ayres, J. G., Higgins, B., Chilvers, E. R., Ayre, G., Blogg, M., & Fox, H. (2004). Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate‐to‐severe) allergic asthma. Allergy. https://doi.org/10.1111/j.1398-9995.2004.00533.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.